6th World Congress on Leishmaniasis
20 May
Plenary Session
Access to treatment
Conducted by:
- Margriet den Boer, MSF, UK & Ireland
- Bernard Pécoul, DNDi, Geneva, Switzerland
Participants:
- Robert Sebbag, Former Vice President Access to Medicines, Sanofi-Aventis
- JA Ruiz-Postigo, WHO/Leishmaniasis programme, Geneva, Switzerland
- Nirmal Kumar Ganguly, Visiting professor of eminence Translational Health Science & Technology Institute NCR Biotech Science Cluster, Faridabad, India
- Judy Stone, Contributor, Pharma and Health for Forbes, USA
Parallel Sessions
Challenges on implementation and development of clinical trials
Chair: Nathalie Strub-Wourgaft, DNDi, Geneva, Switzerland
Co-chair: Jane Mbuy, KEMRI, Nairobi Kenya
| Methodology and study design Vishal Goyal, DNDi, India |
| Good clinical practices Varalakshmi Elango, Former WHO/TDR |
| From clinical trials to access Nathalie Strub-Wourgaft, DNDi, Geneva, Switzerland |
Platform for research and control
Chair: Monique Wasunna, DNDi, Nairobi, Kenya
Co-chair: Jorge Alvar, DNDi, Geneva, Switzerland
|
The Leishmaniasis East African Platform: contributing to strengthening clinical trial capacity, treatment and control of visceral leishmaniasis in Eastern Africa Asrat Hailu, University of Addis Ababa, Addis Ababa, Ethiopia |
|
Leishmaniasis research network (RedLeish): experience in Latin America Joelle Rode, DNDi, Rio de Janeiro, Brazil |
|
Building a joint effort to optimally assess the efficacy of visceral leishmaniasis therapies: a VL data repository and network Philippe Guerin (Oxford University, Oxford, UK) |
|
Kalacore-Bi regional support for the control and elimination of visceral leishmaniasis in Africa and Asia: developing an integrated approach to implementation and research Simon Croft, London School of Hygiene and Tropical Medicine, London, UK |
